WHX Lagos 2025 is set to be West Africa’s largest healthcare event, taking place from 2-4 June 2025 at the Landmark Centre in Lagos, Nigeria.
This event is not just an exhibition, but it’s a movement that brings together healthcare leaders, innovators, policymakers, and businesses from Africa and beyond.
Murli Krishna Pharma Pvt. Ltd is a leading Indian pharmaceutical company with a robust vision to impact the healthcare sector in Nigeria.
Under the leadership of Dr. Satya Vadlamani, Murli Krishna Pharma is set to address the healthcare needs of Nigeria, starting from its exhibition at WHX Lagos 2025.
WHX Lagos 2025: A Hub for Healthcare Transformation…
WHX Lagos 2025 is the 12th edition of an annually held event, formerly known as Medic West Africa and Medlab West Africa.
The collaboration between WHX Lagos and WHX Labs Lagos provides a unified platform for healthcare providers and laboratory science professionals.
Over 500+ exhibitors across Africa will showcase their latest medical devices, pharmaceuticals, digital health and diagnostics.
The expo aims to foster connections, drive knowledge exchange, and showcase groundbreaking advancements.
WHX Lagos 2025 will feature interactive sessions, expert-led discussions, and a focus on leadership, investment opportunities, digital health solutions, diagnostics, and innovations.
Underling the national significance of this expo, the Minister of Health, Professor Muhammad Ali Pate will inaugurate the event.
Overview of Nigeria’s Healthcare Landscape…
Nigeria’s pharmaceutical market is one of the largest in Africa, which is valued about $4 billion in comparison to the total healthcare spend of $10 billion.
The region is also faced with several challenges:
Over 70% of medicines are imported, highlighting a reliance on foreign supply.
Out-of-pocket expenditure is high, with up to 62% of healthcare costs paid directly by patients.
The local pharmaceutical industry, with more than 130 companies, mainly focuses on essential medicines, leaving gaps in advanced therapies and innovative drug delivery.
Quality concerns persist, with counterfeit and unlicensed medicines still in circulation, though efforts like stricter registration and track-and-trace technologies are improving the situation.
The Nigerian healthcare sector is rapidly growing despite the above challenges.
The pharmaceutical industry saw a growth of 80% between 2018 and 2023. The introduction of the National Health Insurance Act is expected to further expand access and change how healthcare solutions are acquired and used.
Murli Krishna Pharma (MKPPL) Core Vision and Values
Murli Krishna Pharma (MKPPL) is an Indian pharmaceutical company driven by Research and Development (R&D), innovation, quality, and a commitment to improving patient outcomes.
MKPPL’s vision is to set new standards in the industry through cutting-edge nano encapsulation and novel drug delivery systems (NDDs), aiming for a global turnover of $200 million by 2026.
Here are the key pillars of Murli Krishna Pharma’s vision:
Innovation in Drug Delivery: Specializes in advanced technologies like nano encapsulation, which enhances the efficacy and safety of medicines.
Patient-Centric Approach: MKPPL collaborates with healthcare professionals, regulatory bodies, and academia to address unattended medical needs.
Quality and Compliance: Products meet stringent international standards, with approvals from the EU, WHO, GCC, and Jordanian FDA.
Sustainable Impact: Murli Krishna Pharma aims for long-term growth by nurturing talent, expanding its product pipeline, and fostering a culture of excellence.
Murli Krishna Pharma’s Impact and Offerings…
MKPPL is recognized as a leading pharmaceutical company in India, with over 200 clients, including 64 international companies, and a turnover exceeding $6 million.
The company’s growth rate has been significant, with over 60% cumulative growth in the last three years.
Here are the product highlights of MKPPL:
Pre-Finished Formulation Intermediates (PFIs): MKPPL offers a wide range of PFIs and finished dosage forms, such as pellets, micro pellets, capsules, injectables, tablets, and suspensions.
Innovative Treatments: MKPPL’s ‘Transdermal Lotion’ addressing anemia provides an easy and effective alternative to traditional oral iron supplements. This innovation is particularly suitable for populations with high anemia rates.
Focus on R&D: Dr. Satya Vadlamani, MD, invests heavily in research and development (R&D) ensuring its products are developed to specific patient needs and are reliable and effective.
MKPPL’s Long-Term Vision for Nigeria
Murli Krishna Pharma’s participation in WHX Lagos 2025 expo from 2-4 June 2025 signals a strong focus on making a lasting impact in Nigeria’s healthcare sector.
Here’s how MKPPL’s vision aligns with Nigeria’s needs:
Reducing Import Dependency: By introducing advanced drug delivery technologies and high-quality formulations to Nigeria, MKPPL can help reduce the country’s reliance on imported medicines and support local manufacturing.
Improving Access and Affordability: With innovative products like PFIs and transdermal formulations, MKPPL can offer more affordable and effective treatments, addressing key health challenges such as anemia and infectious diseases.
Supporting Healthcare Innovation: MKPPL’s expertise in novel drug delivery systems (NDDs) and collaboration with Nigerian stakeholders can contribute to the growing momentum in Nigeria’s healthcare innovation ecosystem, which is already seeing success in telemedicine and mobile health applications.
Ensuring Quality and Safety: MKPPL is committed to stringent quality standards which will help to combat the issue of counterfeit medicines, ensuring Nigerian patients receive safe and effective treatments.
Collaboration and Sustainable Growth…
The future of healthcare in Nigeria depends on partnerships between local and international players, public and private sectors, and innovators and policymakers.
Murli Krishna Pharma’s approach—grounded in innovation, quality, and collaboration—positions it as a valuable partner for Nigeria’s healthcare transformation.
By participating in WHX Lagos 2025, MKPPL is not just showcasing its products but also building relationships, sharing knowledge, and exploring opportunities for local manufacturing, technology transfer, and capacity building.
This aligns perfectly with Nigeria’s goals of improving healthcare access, reducing costs, and fostering a culture of innovation in the region.
Frequently Asked Questions…
*What is Murli Krishna Pharma Pvt Ltd?
Murli Krishna Pharma Pvt Ltd (MKPPL) is an Indian pharmaceutical company known for its novel drug delivery systems and manufacturing high-quality medicines using advanced technologies like nano and liposomal encapsulation.
It specializes in pre-finished formulation intermediates (PFIs), finished dosage forms, and contract research and manufacturing services for global healthcare markets.
*Is Murli Krishna Pharma participating in WHX Lagos 2025 expo?
Yes, Murli Krishna Pharma Pvt Ltd is participating in the WHX Lagos 2025 expo at stand No. #H2.A14. You can explore the latest healthcare solutions.
*Who is the MD of Murli Krishna Pharma Pvt Ltd?
The Managing Director of Murli Krishna Pharma Pvt Ltd is Dr. Satya Ramani Vadlamani.
*How does MKPPL plan to impact the Nigerian healthcare system?
By introducing advanced, affordable medicines and novel drug delivery technologies, such as transdermal lotions, MKPPL aims to address local health challenges like anemia.
It also plans to collaborate with local partners for manufacturing, capacity building, and ensuring a sustainable healthcare solution in the region.
*What is the benefit for patients from MKPPL’s vision?
Healthcare solutions will be effective, safer, and patients will have access to easier-to-use medicines, which improves treatment outcomes and reduces side effects.
*Will medicines be affordable with MKPPL’s intervention in Nigeria?
Yes, MKPPL aims to make medicines more affordable in Nigeria by leveraging cost-effective manufacturing and local partnerships, which can help lower prices and increase accessibility for patients.
